Sagar Lonial

Emory Healthcare — United States

Medicine · Health Sciences

116h-index66.8kcitations1.5kworks1.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(1075), Protein Degradation and Inhibitors(517), Peptidase Inhibition and Analysis(260), Cancer Treatment and Pharmacology(173), Ubiquitin and proteasome pathways(143)

Publications1.5k total

Longitudinal Profiling of Tumor and Immune Compartments Uncovers Patterns of Dysregulation and Associations with Response in Multiple Myeloma
Blood Cancer Discovery·2025Open Access
Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma
Blood Cancer Journal·2025Open Access
Table S4 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel
2025Open Access
Supplementary Table S1 from Impaired SARS-CoV-2 Variant Neutralization and CD8<sup>+</sup> T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections
2025Open Access
Supplementary Figures from Impaired SARS-CoV-2 Variant Neutralization and CD8<sup>+</sup> T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections
2025Open Access
Supplementary Tables S2-S4 from Impaired SARS-CoV-2 Variant Neutralization and CD8<sup>+</sup> T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections
2025Open Access
Figure S1 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel
2025Open Access
Figure S2 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel
2025Open Access
Dreaming of a better future: drug development in myeloma
Blood Advances·2025Open Access
Evidence for pre-existing myeloma cells with a gene expression pattern associated with resistance to BCMA CAR T cells.
Blood·2025Open Access
Multiple myeloma genetic alterations have distinct repertoires and prognostic implications in African and european ancestries
Blood·2025Open Access
Final Results of randomized Phase II study of daratumumab, ixazomib, and dexamethasone (DId, ARM A) vs daratumumab, bortezomib and dexamethasone (DVd) followed by daratumumab, did (Arm B) in newly diagnosed multiple myeloma (DeRIVE) study
Blood·2025Open Access
NSD2 expression remodels DNA methylation, creating a targetable epigenetic dependency in t(4;14) multiple myeloma
Blood·2025
Characterization of NDMM patients treated with daratumumab, lenalidomide, bortezomib and dexamethasone who fail to achieve a VGPR or have early progression
Blood·2025Open Access
Talquetamab bridging therapy for B-cell maturation antigen chimeric antigen receptor T-cell in Relapsed/Refractory multiple myeloma
Blood·2025Open Access
An immune proteomic atlas of 300 million bone marrow cells reveals prognostic cell states in multiple myeloma
Blood·2025
Combinations of high risk cytogenetic events in multiple myeloma drive distinct immune remodeling patterns and worse outcomes
Blood·2025Open Access
CAR-hematotox score for predicting outcomes among myeloma patients receiving BCMA targeting CART constructs (ide-cel and cilta-cel)
Blood·2025
Iberdomide plus daratumumab and dexamethasone (IberDd) in patients with newly diagnosed multiple myeloma by renal function: A subgroup analysis of the CC-220-MM-001 trial
Blood·2025
Real world evidence comparing idecabtagene vicleucel (Ide-cel, Abecma) versus ciltacabtagene autoleucel (Cilta-cel, Carvykti) chimeric antigen receptor T-cell (CART) therapy among patients with Relapsed/Refractory multiple myeloma (RRMM)
Blood·2025Open Access
page 1 of 76Next →

Frequent Co-authors

Paul G. Richardson(29), Kenneth C. Anderson(28), Jesús F. San Miguel(21), S. Vincent Rajkumar(18), Philippe Moreau(17), Pieter Sonneveld(16), Meletios Α. Dimopoulos(15), Sundar Jagannath(15), Brian G.M. Durie(15), Hartmut Goldschmidt(14), Robert Z. Orlowski(14), Joan Bladé(13), Hermann Einsele(13), Antonio Palumbo(12), Michèle Cavo(12), Thierry Façon(11), Shaji Kumar(10), Saad Z. Usmani(10), María‐Victoria Mateos(9), Mario Boccadoro(9)